Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Oculis Holding AG

Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. The company develops innovative product candidates for various eye conditions.

Oculis

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

Following our recent Phase 2 RELIEF data for licaminlimab (also known as OCS-02), our novel anti-TNFα antibody eye drop candidate, the Oculis team had the opportunity to attend the 2024 @European Dry Eye Society Congress (#EuDEC 2024). We enjoyed the opportunity to discuss the data, which delivered further evidence to support the potential of our #PrecisionMedicine approach for the treatment of dry eye disease (#DED), a growing area of unmet need that affects nearly 40 million people in the US alone. 
 
The RELIEF trial was an exploratory study designed to achieve three specific objectives: to evaluate the efficacy of licaminlimab on the signs of DED, to confirm the TNFR1 genetic biomarker as a predictor of response and to select the primary sign efficacy endpoint for a future Phase 3 trial. The trial met all three of these objectives, with positive topline data complementing two prior successful Phase 2 studies, during which the TNFR1 genetic biomarker was identified as a predictor of high responders to therapy. Excitingly, improvement of multiple signs of DED were observed in the full trial population, with more pronounced effect in the subpopulation with a TNFR1-related genotype, consistent with earlier trial results and laying the groundwork for progression towards a Phase 3 study. 
 
For more information on the RELIEF topline results including important information on forward-looking statements, see our press release here: ur press release here: https://bit.ly/4bWdQw0

EURETINA and Oculis have come together to pay a lasting tribute to Professor Tadayoni’s legacy. In this effort, EURETINA has established the Ramin Tadayoni Award supported by Oculis. 

Professor Tadayoni was a world-renowned retina specialist who contributed greatly to the field of ophthalmology and to Oculis’ success as Retina Chair of the company’s Scientific Advisory Board and as Chief Scientific Officer, at the time of his unexpected passing earlier this year.

Throughout his career, Professor Tadayoni was highly committed to advancing retinal research and education. This annual award will combine both of these profound values by supporting the next generation of talented ophthalmologists who have demonstrated outstanding potential in retinal research and are driving forward innovation in the field. 

For additional details on this announcement, see our press release here: https://bit.ly/4ezIZY9

For more information about the Ramin Tadayoni Award, including eligibility requirements and how to apply, visit: https://lnkd.in/eFgZen6f

#eyehealth #ophthalmology #biotech #biopharma #eyedisease #education #researchgrant

It was a privilege to join leading ophthalmology experts during Eyecelerator @ASCRS 2024, to discuss the treatment landscape and recent advancements that are accelerating innovation.

At Oculis, our innovative and diversified pipeline continues to advance, and we remain laser-focused on delivering our key programs: OCS-01 in DME, OCS-02 in DED and OCS-05 in Acute Optic Neuritis. We are confident and excited as we move into a catalyst-rich 2024 and look forward to updating everyone on the upcoming RELIEF trial readout planned by end of Q2 and  the ACUITY trial readout of OCS-05 in Acute Optic Neuritis planned in Q4.

Thank you again to the conference organizers for an excellent event!

#eyehealth #ophthalmology #biotech #biopharma #eyecelerator #ASCRS

We are thrilled to welcome industry leaders, @Robert K. Warner and Dr. Arshad M. Khanani, to our Board of Directors. Mr. Warner, who brings substantial global and U.S. commercial leadership expertise, and Dr. Khanani, a world-renowned retina expert, will be invaluable additions to our already strong Board as we progress toward important inflection points. Welcome to Oculis! 
 
For full bios and additional detail on Oculis’ Annual General Meeting, including important information on forward-looking statements, see our press release here: https://bit.ly/3VkeKwz
 
#eyehealth #ophthalmology #biotech #biopharma #eyedisease #leadership

Great article from Ghislaine Bloch in Bilan Magazine featuring Oculis and the progress made to date to fulfill our mission of saving sight and improving eye care

On Sunday, Eric Donnenfeld, M.D., presented the positive topline results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for inflammation and pain following cataract surgery at the 2024 ASCRS Annual Meeting, which took place on April 5-8, 2024 in Boston, MA.
 
The Phase 3 OPTIMIZE-1 trial met its primary endpoints, demonstrating superior reduction in inflammation and pain vs. vehicle following cataract surgery. Topline data from the second Phase 3 OPTIMIZE-2 trial is anticipated in Q4 2024 and is expected to support NDA submission. If approved, OCS-01 would become the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery. 
 
For additional details, including important information on forward-looking statements, see our press release here: https://bit.ly/3PTXbQV
 
#eyehealth #ophthalmology #biotech #biopharma #ASCRS

	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
revenue			248K -	240K 3.23%			239.50K -
cost of revenue			5.37M -	6.70M 24.77%			6.17M -
gross profit			-5.12M -	-6.46M 26.12%			-5.93M -
selling and marketing expenses
general and administrative expenses	985K -	1.47M 49.54%	2.07M 40.63%	2.78M 34.01%	1.67M 39.84%	1.88M 12.69%	4.42M 134.86%	4.27M 3.33%	3.65M 14.65%	4.10M 12.39%	4.05M 1.15%	5.21M 28.65%	4.66M 10.68%
selling general and administrative expenses	985K -	1.47M 49.54%	2.07M 40.63%	2.78M 34.01%	1.67M 39.84%	1.88M 12.69%	4.42M 134.86%	4.27M 3.33%	3.65M 14.65%	4.10M 12.39%	4.05M 1.15%	5.21M 28.65%	4.66M 10.68%
research and development expenses	1.78M -	3.53M 98.48%	5.37M 52.21%	6.70M 24.77%	4.59M 31.48%	6.89M 50.02%	6.17M 10.39%	6.20M 0.40%	8.87M 43.14%	8.03M 9.50%	10.86M 35.21%	16.46M 51.67%	13.00M 21.05%
other expenses													476K -
cost and expenses	2.90M -	4.68M 61.23%	8.36M 78.53%	10.88M 30.21%	6.87M 36.85%	11.11M 61.69%	29.05M 161.37%	10.74M 63.01%	12.96M 20.60%	12.18M 5.98%	15.33M 25.80%	22.48M 46.69%	18.13M 19.36%
operating expenses	2.90M -	4.68M 61.23%	2.99M 36.19%	4.18M 39.98%	6.87M 64.35%	11.11M 61.69%	22.87M 105.82%	10.74M 53.02%	12.96M 20.60%	12.18M 5.98%	15.33M 25.80%	22.48M 46.69%	18.13M 19.36%
interest expense	1.54M -	1.53M 1.04%			1.83M -	1.32M 27.86%		17K -	11K 35.29%	12K 9.09%	41K 241.67%	87K 112.20%	264K 203.45%
ebitda	-2.84M -	-4.61M 62.64%	-7.16M 55.21%	-9.20M 28.53%	-6.74M 26.80%	-10.98M 62.96%	-10.32M 6.01%	-10.51M 1.84%	-12.37M 17.66%	-11.45M 7.38%	-14.67M 28.11%	-21.74M 48.13%	-19.79M 8.97%
operating income	-2.90M -	-4.68M 61.19%	-7.20M 53.71%	-9.24M 28.39%	-6.87M 25.60%	-11.11M 61.69%	-10.35M 6.83%	-10.74M 3.78%	-12.96M 20.60%	-12.18M 5.98%	-15.33M 25.80%	-22.48M 46.69%	-18.13M 19.36%
depreciation and amortization	61K -	53K 13.11%	33.50K 36.79%	33.50K 0%	74K 120.90%	77K 4.05%	33.50K 56.49%	19K 43.28%	73K 284.21%	74K 1.37%	73K 1.35%	89K 21.92%	122K 37.08%
total other income expenses net	-545K -	659K 220.92%	-2.55M 487.63%	-3.06M 19.95%	-1.30M 57.51%	3.18M 344.47%	-18.97M 696.12%	-2.22M 88.32%	-5.08M 129.09%	-972K 80.86%	-1.27M 31.17%	1.10M 186.51%	-2.04M 285.04%
income before tax	-4.99M -	-5.54M 11.01%	-9.75M 76.14%	-12.30M 26.18%	-9.95M 19.14%	-9.20M 7.55%	-29.33M 218.89%	-12.76M 56.48%	-17.53M 37.34%	-12.51M 28.62%	-16.06M 28.38%	-20.81M 29.55%	-20.17M 3.06%
income tax expense	-10K -	11K 210%	32K 190.91%	42K 31.25%	6K 85.71%	-14K 333.33%	118K 942.86%	114K 3.39%	-116K 201.75%	-13K 88.79%	30K 330.77%	30K 0%	18K 40%
net income	-4.98M -	-5.55M 11.48%	-9.78M 76.34%	-12.34M 26.20%	-9.95M 19.36%	-9.18M 7.75%	-29.45M 220.66%	-12.88M 56.27%	-17.41M 35.23%	-12.50M 28.22%	-16.09M 28.75%	-20.84M 29.49%	-20.19M 3.11%
weighted average shs out	32.73M -		3.35M -	3.39M 1.25%	32.73M 864.92%		23.27M -	33.57M 44.22%	36.28M 8.08%		36.62M -
weighted average shs out dil	32.73M -		3.35M -	3.39M 1.25%	32.73M 864.92%		23.27M -	33.57M 44.22%	36.28M 8.08%		36.62M -
eps	-0.15 -	0 100%	-2.92 Infinity%	-3.64 24.66%	-0.30 91.76%	0 100%	-1.27 Infinity%	-0.38 70.08%	-0.48 26.32%	0 100%	-0.44 Infinity%	0 100%	0
epsdiluted	-0.15 -	0 100%	-2.92 Infinity%	-3.64 24.66%	-0.30 91.76%	0 100%	-1.27 Infinity%	-0.38 70.08%	-0.48 26.32%	0 100%	-0.44 Infinity%	0 100%	0

COM:OCULIS

Oculis

Last Close

14.75

22/11 21:00

Market Cap

467.04M

Beta: -

Volume Today

39.61K

Avg: -

Preview